文献速递类风湿关节炎

早期类风湿关节炎糖皮质激素七年耐受性:ESPOIR队列数据

Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort.
PubMed 文献 · Ann Rheum Dis · 2017-02-17

基于ESPOIR早期关节炎队列602例RA患者(病程<6个月),比较随访期间使用与未使用糖皮质激素者的复合终点(死亡、心血管事件、严重感染、骨折)。386例(64.1%)接受低剂量泼尼松(平均3.1±2.9 mg/天),中位随访7年,加权Cox分析显示两组复合结局无差异(HR=0.889,95%CI 0.620-1.273,p=0.520),支持极低剂量GC在早期活动性RA中的良好安全性。

要点

  • 早期RA中极低剂量泼尼松(平均3.1 mg/天)随访7年未增加复合不良结局风险。
  • 使用GC者基线病情更活动、残疾更重、CRP和ACPA更高,提示存在适应证混杂。
  • 感染在GC组更常见但未达统计学显著(p=0.09)。

核心结论

  • ESPOIR队列7年分析支持极低剂量糖皮质激素用于早期活动性RA具有良好安全性。

研究设计与样本

  • 基于ESPOIR早期关节炎队列602例RA患者(病程<6个月),按随访期间是否至少使用一次GC分为两组,中位随访7年(IQR 0.038-7.65)。
  • 主要结局为死亡、心血管疾病(含心肌缺血、脑血管意外和心力衰竭)、严重感染和骨折的复合终点。

主要发现

  • 602例患者中476例(79%)为女性,平均年龄48±12岁;386例(64.1%)接受GC,使用低剂量泼尼松平均3.1±2.9 mg/天。
  • 263例(68%)在最初6个月内开始GC,GC总治疗平均时长1057±876天。
  • 共65起事件(7例死亡、14例心血管疾病、19例严重感染、25例骨折),GC组44起、无GC组21起(p=0.520)。
  • 感染在GC组更频繁但未达统计学显著(p=0.09)。
  • 采用倾向评分和逆概率治疗加权的加权Cox分析(纳入年龄、性别、高血压史和GC治疗),两组结局无差异(p=0.520;HR=0.889;95%CI 0.620-1.273)。

临床怎么用

  • 对于早期活动性RA,可考虑使用极低剂量泼尼松(本队列平均约3.1 mg/天),7年随访未观察到复合不良结局增加。
  • 使用GC者基线病情更活动、残疾更重、CRP和ACPA更高,临床决策时需考虑适应证混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To explore the 7-year tolerability profile of glucocorticoids (GC) for early rheumatoid arthritis (RA). METHODS: We examined data for 602 patients with RA from the early arthritis Etude et Suivi des POlyarthrites Indifférenciées Récentes (ESPOIR) cohort (<6 months disease duration) stratified into two groups: with or without GC treatment at least once during follow-up (median 7 years (IQR 0.038-7.65)). The main outcome was a composite of death, cardiovascular disease (including myocardial ischaemia, cerebrovascular accident and heart failure), severe infection and fracture. RESULTS: Among the 602 patients with RA (476 women (79%), mean age 48±12 years), 386 with GC (64.1%) received low-dose prednisone (mean 3.1±2.9 mg/day for the entire follow-up): 263 started GC during the first 6 months (68%), and the mean duration of total GC treatment was 1057±876 days. As compared with patients without GC (216 (35.9%)), those with GC showed greater use of non-steroidal anti-inflammatory drugs, synthetic and biological disease-modifying antirheumatic drugs and had more active disease disability, higher C reactive protein and anticitrullinated protein antibody levels. Among 65 events (7 deaths, 14 cardiovascular diseases, 19 severe infections and 25 fractures), 44 and 21 occurred in patients with and without GC (p=0.520). Infections were more frequent, although not significantly, in patients with than without GC (p=0.09). On weighted Cox proportional-hazards analysis, with use of propensity score and inverse-probability-of-treatment weighting, and including age, gender, history of hypertension and GC treatment, outcomes did not differ with and without GC (p=0.520; HR=0.889; 95% CI 0.620 to 1.273). CONCLUSIONS: This 7-year analysis of the ESPOIR cohort supports the good safety profile of very low-dose GC for early active RA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Roubille C, Rincheval N, Dougados M, et al. Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort. Ann Rheum Dis. 2017. PMID: 28213564. doi:10.1136/annrheumdis-2016-210135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。